RPRX vs OR

For growth investors, OR Royalties Inc.

(OR) is the stronger pick with 47. 5% revenue growth year-over-year, versus 5. 1% for Royalty Pharma plc (RPRX). Royalty Pharma plc (RPRX) offers the better valuation at 28. 2x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 28.

2x versus OR Royalties Inc. at 34. 9x. On forward P/E, Royalty Pharma plc is actually cheaper at 10. 4x.

Over the past 5 years, OR Royalties Inc.

(OR) delivered a total return of +199. 7%, compared to +33. 3% for Royalty Pharma plc (RPRX). Over 10 years, the gap is even starker: OR returned +210. 1% versus RPRX's +24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

45β versus OR Royalties Inc. 's 0. 54β — meaning OR is approximately 19% more volatile than RPRX relative to the S&P 500. On balance sheet safety, OR Royalties Inc. (OR) carries a lower debt/equity ratio of 1% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), OR Royalties Inc.

(OR) is pulling ahead at 47. 5% versus 5. 1% for Royalty Pharma plc (RPRX). On earnings-per-share growth, the picture is similar: OR Royalties Inc. grew EPS 825. 0% year-over-year, compared to 24. 1% for Royalty Pharma plc. Over a 3-year CAGR, OR leads at 20. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OR Royalties Inc.

(OR) is the more profitable company, earning 74. 3% net margin versus 32. 4% for Royalty Pharma plc — meaning it keeps 74. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OR leads at 72. 9% versus 65. 6% for RPRX. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Royalty Pharma plc (RPRX) trades at 10.

4x forward P/E versus 18. 9x for OR Royalties Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OR: 14. 9% to $44. 50.

All stocks in this comparison pay dividends.

Royalty Pharma plc (RPRX) offers the highest yield at 1. 3%, versus 0. 5% for OR Royalties Inc. (OR).

For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 1. 3% yield). Both have compounded well over 10 years (RPRX: +24. 0%, OR: +210. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RPRX (Healthcare) and OR (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RPRX is a mid-cap quality compounder stock; OR is a small-cap high-growth stock. RPRX pays a dividend while OR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.